Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Public ClinicalTrials.gov record NCT03960840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Study identification
- NCT ID
- NCT03960840
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 217 participants
Conditions and interventions
Conditions
Interventions
- Ibrutinib Drug
- Rapcabtagene autoleucel single agent Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2019
- Primary completion
- Jun 29, 2027
- Completion
- Jun 29, 2027
- Last update posted
- Apr 16, 2026
2019 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California LA | Los Angeles | California | 90095 | — |
| Stanford University Medical Center | Stanford | California | 94305-5826 | — |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Uni of Chi Medi Ctr Hema and Onco | Chicago | Illinois | 60637 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Mass Gen Hosp Cancer Center | Boston | Massachusetts | 02114 | — |
| University of Pennsylvania Clinical | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37221 | — |
| St Davids South Austin Medical Ctr | Austin | Texas | 78704 | — |
| Uni Of TX MD Anderson Cancer Cntr | Houston | Texas | 77030 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03960840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03960840 live on ClinicalTrials.gov.